Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersNinghui Mao(Memorial Sloan Kettering Cancer Center), Brett S. Carver(Memorial Sloan Kettering Cancer Center)Nature CommunicationsAugust 20, 202110.1038/s41467-021-25341-9Cited by 30SaveCiteExport RISWatch citationsRelated PapersOrganoid Cultures Derived from Patients with Advanced Prostate Cancer|Cell|2014|1.6kTumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer|Cancer Cell|2020|252